CDEK
← All drugs Report issue

anti-bcma/gprc5d car-t cell

Cell therapyexperimental

Clinical trial activity

8 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2022 (NCT05509530)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • BCMAImmunity, passive

    BCMA immunity, passive

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07195617N/AOct 10, 2025Guangzhou Bio-gene Technology Co., Ltd., Nanjing Medical University
NCT07196124Early Phase 1 (Phase 1)Oct 10, 2025Guangzhou Bio-gene Technology Co., Ltd.
NCT07003568Phase 1May 25, 2025Government of China, Jiao Tong University, Shanghai Liquan Hospital
NCT07032129Phase 1/Phase 2 (Phase 2)Apr 29, 2025Essen Biotech
NCT06793475N/AApr 9, 2025China Academy of Chinese Medical Sciences
NCT06515262N/AJul 1, 2024Guangzhou Bio-gene Technology Co., Ltd., People's Liberation Army of China
NCT06644443Phase 1/Phase 2 (Phase 2)Jul 15, 2023Shenzhen University
NCT05509530Phase 2May 1, 2022Xuzhou Medical University
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Guangzhou Bio-gene Technology Co., Ltd.For profit3222024
China Academy of Chinese Medical SciencesAcademic/Hospital1112025
Essen BiotechFor profit1112025
Government of ChinaGovernment1112025
Jiao Tong UniversityAcademic/Hospital1012025
Nanjing Medical UniversityAcademic/Hospital1012025
People's Liberation Army of ChinaGovernment1112024
Shanghai Liquan HospitalAcademic/Hospital1012025
Shenzhen UniversityAcademic/Hospital1112023
Xuzhou Medical UniversityAcademic/Hospital1112022
10 organizations
Page 1 / 1